Curated News
By: NewsRamp Editorial Staff
July 02, 2025
Soligenix's HyBryte(TM) Shows Promise in CTCL Treatment
TLDR
- Soligenix's HyBryte(TM) shows a 75% reduction in disease severity in early trials, positioning it as a potential leader in CTCL treatment by 2026.
- HyBryte(TM), a light-activated topical therapy, targets early-stage mycosis fungoides in CTCL patients, with phase 3 trial results expected in late 2026.
- Soligenix's HyBryte(TM) offers hope for CTCL patients, promising a significant improvement in quality of life through innovative, targeted treatment options.
- Discover how Soligenix's HyBryte(TM) is revolutionizing CTCL treatment with a 75% efficacy rate in early trials, a breakthrough in rare disease therapy.
Impact - Why it Matters
This news is significant because it highlights a potential breakthrough in the treatment of cutaneous T-cell lymphoma (CTCL), a rare and often debilitating form of non-Hodgkin's lymphoma. The promising interim results from the University of Pennsylvania study suggest that HyBryte(TM) could offer a new, effective treatment option for patients, improving their quality of life and potentially changing the standard of care for CTCL. The anticipation of phase 3 trial results in 2026 also marks an important milestone in the development of this therapy, offering hope to patients and their families.
Summary
In a recent investment webinar hosted by Allele Capital, Soligenix (NASDAQ: SNGX) executives Dr. Christopher Schaber and Dr. Christopher Pullion provided updates on the company's HyBryte(TM) clinical development, highlighting promising interim results from an investigator-initiated study at the University of Pennsylvania. The study, led by Dr. Ellen Kim, showed that 75% of the first eight patients who completed 18 weeks of treatment with HyBryte(TM) experienced a greater than 50% reduction in disease severity. Soligenix, a late-stage biopharmaceutical company, is focusing on rare diseases and unmet medical needs, with HyBryte(TM) being its lead asset for treating cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin's lymphoma. The company anticipates top-line results from its phase 3 trial in the second half of 2026.
HyBryte(TM) is a topical therapy activated by visible light, targeting early-stage mycosis fungoides, which accounts for nearly 90% of CTCL cases. This innovative treatment approach could significantly improve the quality of life for patients suffering from this debilitating condition. For more detailed information, visit the BioMedWire article.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix's HyBryte(TM) Shows Promise in CTCL Treatment
